Literature DB >> 11585303

Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.

W A Breeman1, M de Jong, D J Kwekkeboom, R Valkema, W H Bakker, P P Kooij, T J Visser, E P Krenning.   

Abstract

In vivo somatostatin receptor-mediated scintigraphy has proven to be a valuable method for the visualisation of neuroendocrine tumours and their metastases. A new application is the use of radiolabelled analogues for somatostatin receptor-mediated therapy. This paper presents a review on the basic science, historical background and current knowledge of somatostatin receptor subtypes and their expression in neuroendocrine tumours. New somatostatin analogues, new chelators, "new" radionuclides and combinations thereof are also discussed. Due attention is given to limitations and future perspectives of somatostatin receptor-mediated imaging and therapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11585303     DOI: 10.1007/s002590100502

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  43 in total

1.  Visualisation of the normal adrenals at SPET examination with 111In-pentetreotide.

Authors:  Hans Jacobsson; Staffan Bremmer; Stig A Larsson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-05-24       Impact factor: 9.236

2.  Radiolabelling DOTA-peptides with 68Ga.

Authors:  Wouter A P Breeman; Marion de Jong; Erik de Blois; Bert F Bernard; Mark Konijnenberg; Eric P Krenning
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-01-18       Impact factor: 9.236

3.  What can gallium-68 PET add to receptor and molecular imaging?

Authors:  Adil Al-Nahhas; Zarni Win; Teresa Szyszko; Aviral Singh; Sameer Khan; Domenico Rubello
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12       Impact factor: 9.236

Review 4.  Somatostatin receptor scintigraphy in thoracic diseases.

Authors:  P Ameri; F Gatto; M Arvigo; G Villa; E Resmini; F Minuto; G Murialdo; D Ferone
Journal:  J Endocrinol Invest       Date:  2007-11       Impact factor: 4.256

Review 5.  Targeted therapy in advanced well-differentiated neuroendocrine tumors.

Authors:  Chandrajit P Raut; Matthew H Kulke
Journal:  Oncologist       Date:  2011-02-23

Review 6.  International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.

Authors:  Thomas Günther; Giovanni Tulipano; Pascal Dournaud; Corinne Bousquet; Zsolt Csaba; Hans-Jürgen Kreienkamp; Amelie Lupp; Márta Korbonits; Justo P Castaño; Hans-Jürgen Wester; Michael Culler; Shlomo Melmed; Stefan Schulz
Journal:  Pharmacol Rev       Date:  2018-10       Impact factor: 25.468

Review 7.  (68)Ga-labeled radiopharmaceuticals for positron emission tomography.

Authors:  Dinesh Shetty; Yun-Sang Lee; Jae Min Jeong
Journal:  Nucl Med Mol Imaging       Date:  2010-10-12

8.  68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors.

Authors:  C Pettinato; A Sarnelli; M Di Donna; S Civollani; C Nanni; G Montini; D Di Pierro; M Ferrari; M Marengo; C Bergamini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-14       Impact factor: 9.236

9.  Effects of chelator modifications on (68)Ga-labeled [Tyr (3)]octreotide conjugates.

Authors:  Mai Lin; Michael J Welch; Suzanne E Lapi
Journal:  Mol Imaging Biol       Date:  2013-10       Impact factor: 3.488

10.  DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.

Authors:  Damian Wild; Jörg S Schmitt; Mihaela Ginj; Helmut R Mäcke; Bert F Bernard; Eric Krenning; Marion De Jong; Sandra Wenger; Jean-Claude Reubi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-08-21       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.